Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
Abstract Background Understanding patients' perspectives regarding drug tolerability, in addition to effectiveness, provides a complete picture of the patient experience and supports more informed therapeutic decision-making. The item library of the National Cancer Institute's Patient-Repo...
Saved in:
Main Authors: | Stacy Davis (Author), Teresa Edwards (Author), Lindsey Norcross (Author), Sheri Fehnel (Author), Amélie Beaudet (Author), Marie Eckart (Author), John Fastenau (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation
by: Rusul M. Alwan, et al.
Published: (2021) -
Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
by: Kristin M. Schroeder, et al.
Published: (2023) -
Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
by: Hardin EA, et al.
Published: (2016) -
Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
by: Shun-bin Luo, et al.
Published: (2022) -
The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events
by: Takashi Kawaguchi, et al.
Published: (2018)